¼¼°èÀÇ ¼¶À¯³¶¼º À¯¹æ Áúȯ ½ÃÀå º¸°í¼­(2025³â)
Fibrocystic Breast Condition Global Market Report 2025
»óǰÄÚµå : 1730859
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,183,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 8,938,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,692,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¶À¯³¶¼º À¯¹æ Áúȯ ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¸î ³â°£ °­·ÂÇÑ ¼ºÀåÀÌ Àü¸ÁµË´Ï´Ù. 2029³â¿¡´Â CAGR 6.1%·Î ¼ºÀåÇÒ Àü¸ÁÀ̸ç, 91¾ï ´Þ·¯·Î ¼ºÀåÀÌ ¿¹ÃøµË´Ï´Ù. ¿¹Ãø ±â°£ ÁßÀÇ ¼ºÀåÀº Áø´Ü Åø ¹× Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, Á¤ºÎ Á¶¼º±Ý Áõ°¡, È¿°úÀûÀÎ Ä¡·á¿¡ ´ëÇÑ ¿ä±¸ °íÁ¶, °í·ÉÀÚ Àα¸ È®´ë, °ü¹Î ±â°ü¿¡ ÀÇÇÑ ´ëó, ¿¬±¸ °³¹ß Ȱµ¿ÀÇ È°¹ßÈ­ µî¿¡ ±âÀÎÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ÀÌ ±â°£¿¡ ¿¹»óµÇ´Â ÁÖ¿ä µ¿ÇâÀ¸·Î´Â Àúħ½À¼º À¯¹æ »ý°ËÀåÄ¡ äÅÃ, Àü·«Àû ÆÄÆ®³Ê½Ê ¹× Á¦ÈÞ, ¸ÂÃãÇü ÀÇ·á Áß½Ã, ÀΰøÁö´É(AI) ÅëÇÕ, Áö¼ÓÀûÀÎ ±â¼ú Áøº¸ µîÀÌ ÀÖ½À´Ï´Ù.

À¯¹æ¾Ï À¯º´·ü Áõ°¡´Â ¼¶À¯³¶¼º À¯¹æ Áúȯ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯¹æ¾ÏÀº À¯¹æ ¼¼Æ÷¿¡ ¹ß»ýÇÏ´Â ¾ÏÀÇ ÀÏÁ¾À¸·Î, ÁÖ·Î ¿©¼ºÀÌ ÀÌȯÇÕ´Ï´Ù. °í·ÉÈ­, °Ç°­ÇÏÁö ¸øÇÑ ¶óÀÌÇÁ ½ºÅ¸ÀÏ, À¯ÀüÀû ¼ÒÀÎ, °ËÁø Áõ°¡, ȯ°æ Æø·Î µîÀÇ ¿äÀÎÀÌ ¹ß»ý·ü »ó½Â¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¼¶À¯³¶¼º À¯¹æ Áúȯ(FBC)Àº À¯¼± Á¶Á÷À» Á¶¹ÐÇÏ°Ô ÇÔÀ¸·Î½á À¯¹æ¾Ï À§ÇèÀ» »ó½Â½Ãų ¼ö ÀÖÀ¸¸ç, ±× °á°ú ¼¼Æ÷ÀÇ º¯È­, È£¸£¸ó °¨¼ö¼º Ç×Áø, ¿°ÁõÀÇ Àå±âÈ­ µîÀÌ ÃËÁøµÇ¾î ¾Ï °³¹ßÀ» ÃËÁøÇϴ ȯ°æÀ» ¸¸µé¾î ³¾ ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2024³â 7¿ù ¹Ì±¹¾ÏÇùȸ Facts and Figures´Â ¹Ì±¹ÀÇ »õ·Î¿î À¯¹æ¾Ï »ç·Ê ¼ö°¡ 2023³â 30¸¸ 590·Ê¿¡¼­ 2024³â 31¸¸ 3,510·Ê·Î Áõ°¡ÇÑ °ÍÀ¸·Î Æò°¡µÆ´Ù°í º¸°íÇß½À´Ï´Ù. ±× °á°ú À¯¹æ¾Ï À¯º´·ü Áõ°¡°¡ ¼¶À¯³¶¼º À¯¹æ Áúȯ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

¿ø°Ý ÀÇ·á ¼­ºñ½º Áõ°¡µµ ¼¶À¯³¶¼º À¯¹æ Áúȯ ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¿ø°Ý ÀÇ·á ¼­ºñ½º´Â È­»ó ÅëÈ­, ¸ð¹ÙÀÏ ¾ÖÇø®ÄÉÀ̼Ç, ¿Â¶óÀÎ Ç÷§Æû µîÀÇ µðÁöÅÐ Åë½Å ±â¼úÀ» ÀÌ¿ëÇÏ¿© ¿ø°Ý ÀÇ·á »ó´ã, Áø´Ü, Ä¡·á¸¦ Á¦°øÇÕ´Ï´Ù. ¿ø°ÝÀÇ·á È®´ë´Â µðÁöÅÐ Çコ Ç÷§Æû äÅà Ȯ´ë, ÀÎÅÍ³Ý Á¢±Ù¼º °³¼±, ¿ø°Ý ÇコÄÉ¾î ¼­ºñ½º¿¡ ´ëÇÑ È¯ÀÚ ¼±È£¿¡ ÀÇÇØ ÃßÁøµÇ°í ÀÖ½À´Ï´Ù. ¼¶À¯³¶¼º À¯¹æ ÁúȯÀ» °¡Áø ȯÀÚ¿¡°Ô ¿ø°ÝÀÇ·á´Â ¿ø°ÝÁø·á, ½Ã±âÀûÀýÇÑ Áõ»ó°ü¸®, Àü¹®°¡ ÀÇ·áÁöµµ¸¦ °¡´ÉÇÏ°Ô ÇÏ¿© ´ë¸éÁø·áÀÇ Çʿ伺À» ÁÙÀ̰í ȯÀÚÀÇ ÆíÀǼºÀ» ³ôÀÔ´Ï´Ù. ¿¹¸¦ µé¾î 2023³â 2¿ù ¹Ì±¹¿¡ º»»ç¸¦ µÐ ·ÏÇコ´Â 2022³â Á¶»ç¿¡¼­ ÀÀ´äÀÚÀÇ 80%°¡ ¿ø°ÝÀÇ·á ¼­ºñ½º¸¦ ÀÌ¿ëÇÑ ÀûÀÌ ÀÖ´Ù°í º¸°íÇßÀ¸¸ç, ÀÌ´Â 2021³â 72%¿¡¼­ 8% Æ÷ÀÎÆ® Áõ°¡ÇÑ °ÍÀ» ¹Ý¿µÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿ø°ÝÀÇ·á Á¢±Ù¼º Áõ°¡´Â ¼¶À¯³¶¼º À¯¹æ Áúȯ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ ¹× Àü·«

Á¦4Àå ½ÃÀå-°Å½Ã°æÁ¦ ½Ã³ª¸®¿À ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ½ÅÇü Äڷγª ¹ÙÀÌ·¯½º °¨¿°ÀÇ ¿µÇâ°ú ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼® ¹× Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº° ¹× ±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ ¹× ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å· ¹× ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹® ¹× Àü·«

Á¦36Àå ºÎ·Ï

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Fibrocystic breast condition (FBC) is a noncancerous disorder marked by lumpiness, tenderness, and pain in one or both breasts due to the presence of fibrous tissue and fluid-filled cysts. This common benign breast condition is primarily linked to hormonal fluctuations and mostly affects women of reproductive age. Symptoms often change throughout the menstrual cycle and usually subside after menopause.

Treatment options for fibrocystic breast condition include medications, oral contraceptives, fine-needle aspiration, and other approaches. Medications, such as over-the-counter pain relievers or hormonal therapies in severe cases, help alleviate pain and tenderness. Diagnosis involves various methods, including mammograms, ultrasounds, clinical breast exams, and other diagnostic techniques. The condition is managed in different healthcare settings, including hospitals, clinics, and other medical facilities.

The fibrocystic breast condition market research report is one of a series of new reports from The Business Research Company that provides fibrocystic breast condition market statistics, including the fibrocystic breast condition industry global market size, regional shares, competitors with the fibrocystic breast condition market share, detailed fibrocystic breast condition market segments, market trends, and opportunities, and any further data you may need to thrive in the fibrocystic breast condition industry. This fibrocystic breast condition market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The fibrocystic breast condition market size has grown strongly in recent years. It will grow from $6.74 billion in 2024 to $7.17 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth during the historical period can be attributed to the increasing prevalence of breast cancer, higher healthcare expenditure, urbanization, greater awareness, lifestyle changes, and elevated disposable income.

The fibrocystic breast condition market size is expected to see strong growth in the next few years. It will grow to $9.10 billion in 2029 at a compound annual growth rate (CAGR) of 6.1%. The growth during the forecast period can be attributed to the increasing demand for diagnostic tools and treatments, rising government funding, growing need for effective therapies, an expanding geriatric population, initiatives by public and private organizations, and heightened research and development activities. Key trends expected in this period include the adoption of minimally invasive breast biopsy devices, strategic partnerships and collaborations, a greater emphasis on personalized medicine, the integration of artificial intelligence (AI), and continuous technological advancements.

The increasing prevalence of breast cancer is expected to drive the growth of the fibrocystic breast condition market. Breast cancer is a type of cancer that originates in the cells of the breast and primarily affects women. Factors such as an aging population, unhealthy lifestyles, genetic predisposition, increased screening, and environmental exposures contribute to its rising occurrence. Fibrocystic breast condition (FBC) may elevate the risk of breast cancer by leading to dense breast tissue, which can promote cellular changes, heightened hormone sensitivity, and prolonged inflammation, creating an environment that may facilitate cancer development. For example, in July 2024, the American Cancer Society Facts and Figures reported that the number of new breast cancer cases in the United States is expected to rise from 300,590 in 2023 to 313,510 in 2024. As a result, the growing prevalence of breast cancer is fueling the expansion of the fibrocystic breast condition market.

The increasing availability of telemedicine services is contributing to the growth of the fibrocystic breast condition market. Telemedicine services utilize digital communication technologies, such as video calls, mobile applications, and online platforms, to provide remote medical consultations, diagnosis, and treatment. The expansion of telemedicine is driven by the growing adoption of digital health platforms, improved internet accessibility, and patient preferences for remote healthcare services. For individuals with fibrocystic breast condition, telemedicine enables remote consultations, timely symptom management, and expert medical guidance, reducing the necessity for in-person visits and enhancing patient convenience. For instance, in February 2023, Rock Health, a US-based corporation, reported that 80% of respondents in its 2022 survey had used telemedicine services at some point, reflecting an 8 percentage point increase from 72% in 2021. This increased access to telemedicine is contributing to the expansion of the fibrocystic breast condition market.

Leading companies in the fibrocystic breast condition market are developing advanced diagnostic technologies to enhance diagnostic accuracy and treatment outcomes. Diagnostic devices are tools used to detect, identify, or assess medical conditions and diseases. In August 2024, Izotropic Corporation, a Canada-based medical device company, introduced IzoView, a breast CT imaging system designed to improve breast cancer diagnosis in women with dense breast tissue. The company is seeking regulatory approval through a clinical study aimed at demonstrating the superior diagnostic performance of IzoView when used alongside digital breast tomosynthesis (DBT) compared to DBT alone. With high-resolution 3D imaging capabilities and the advantage of eliminating the need for breast compression, IzoView aims to enhance breast cancer detection rates in women with dense breast tissue, a group at higher risk for developing the disease.

Major players in the fibrocystic breast condition market are Pfizer Inc., Hitachi Medical Systems, Roche Diagnostics, Merck & Co Inc., Bayer AG, Sanofi SA, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Siemens Healthineers AG, Fujifilm Holdings Corporation, Philips Healthcare, Becton Dickinson and Company, GE Healthcare Technologies Inc., Teva Pharmaceutical Industries Ltd, Hologic Inc., Canon Medical Systems Corporation, Hikma Pharmaceuticals plc, Steris Pharma, Lannett Company Inc., Argon Medical Devices Inc., and AdvaCare Pharma USA LLC.

North America was the largest region in the fibrocystic breast condition market in 2024. The regions covered in fibrocystic breast condition report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the fibrocystic breast condition market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The fibrocystic breast condition market consists of revenues earned by entities by providing services such as diagnosis and screening services, surgical interventions, healthcare consultations and follow-ups, medical treatments, and medications. The market value includes the value of related goods sold by the service provider or included within the service offering. The fibrocystic breast condition market also includes sales of hormonal therapies, ultrasound devices, cyst aspiration kits, vitamins, and supplements. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Fibrocystic Breast Condition Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on fibrocystic breast condition market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for fibrocystic breast condition ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The fibrocystic breast condition market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Fibrocystic Breast Condition Market Characteristics

3. Fibrocystic Breast Condition Market Trends And Strategies

4. Fibrocystic Breast Condition Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Fibrocystic Breast Condition Growth Analysis And Strategic Analysis Framework

6. Fibrocystic Breast Condition Market Segmentation

7. Fibrocystic Breast Condition Market Regional And Country Analysis

8. Asia-Pacific Fibrocystic Breast Condition Market

9. China Fibrocystic Breast Condition Market

10. India Fibrocystic Breast Condition Market

11. Japan Fibrocystic Breast Condition Market

12. Australia Fibrocystic Breast Condition Market

13. Indonesia Fibrocystic Breast Condition Market

14. South Korea Fibrocystic Breast Condition Market

15. Western Europe Fibrocystic Breast Condition Market

16. UK Fibrocystic Breast Condition Market

17. Germany Fibrocystic Breast Condition Market

18. France Fibrocystic Breast Condition Market

19. Italy Fibrocystic Breast Condition Market

20. Spain Fibrocystic Breast Condition Market

21. Eastern Europe Fibrocystic Breast Condition Market

22. Russia Fibrocystic Breast Condition Market

23. North America Fibrocystic Breast Condition Market

24. USA Fibrocystic Breast Condition Market

25. Canada Fibrocystic Breast Condition Market

26. South America Fibrocystic Breast Condition Market

27. Brazil Fibrocystic Breast Condition Market

28. Middle East Fibrocystic Breast Condition Market

29. Africa Fibrocystic Breast Condition Market

30. Fibrocystic Breast Condition Market Competitive Landscape And Company Profiles

31. Fibrocystic Breast Condition Market Other Major And Innovative Companies

32. Global Fibrocystic Breast Condition Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Fibrocystic Breast Condition Market

34. Recent Developments In The Fibrocystic Breast Condition Market

35. Fibrocystic Breast Condition Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â